Document Detail


Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation.
MedLine Citation:
PMID:  2840229     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease were evaluated in 12 patients undergoing renal transplantation. A 12-week course beginning 24 hours before transplantation was administered in doses of 800 to 3200 mg/day based on renal function. Acyclovir plasma concentrations were measured by RIA on posttransplant days 1 or 2 and 5, 6, or 7. Mean peak and trough concentrations on days 5, 6 or 7 were 25 and 18 mumol/L, respectively. The pharmacokinetic model predicted acyclovir concentrations with a precision of 4.1 mumol/L and bias of -1.19 mumol/L. Estimates of individual pharmacokinetic parameters were consistent with literature and a priori values. Two of six adverse events were attributable to acyclovir; both resolved with dose modification. The dosage adjustment scheme and pharmacokinetic model performed well, allowing us to safely administer high-dose oral acyclovir immediately after renal transplantation. We are proceeding with a placebo-controlled study to assess efficacy for suppression of posttransplant cytomegalovirus disease.
Authors:
C V Fletcher; B J Chinnock; B Chace; H H Balfour
Related Documents :
16104989 - A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus...
1645949 - Cytomegalovirus pneumonitis after cardiac transplantation.
1315149 - Pharmacokinetics of ganciclovir in renal transplant children.
11884949 - Successful treatment of mucor infection after liver or pancreas-kidney transplantation.
17530009 - Risk factors associated with late cytomegalovirus reactivation after allogeneic stem ce...
8685949 - Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant re...
7422849 - Evaluation of the renal outline by excretory urography.
3046689 - Correlation between low csa plasma concentration and severity of acute gvhd in bone mar...
9453259 - The role of basally synthesized nitric oxide in modulating the renal vasoconstrictor ac...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  44     ISSN:  0009-9236     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  1988 Aug 
Date Detail:
Created Date:  1988-09-08     Completed Date:  1988-09-08     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  158-63     Citation Subset:  AIM; IM    
Affiliation:
Department of Pharmaceutical Services, University of Minnesota, Health Sciences Center, Minneapolis.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acyclovir / administration & dosage,  blood,  pharmacokinetics*
Administration, Oral
Adult
Cytomegalovirus Infections / prevention & control*
Drug Tolerance
Female
Humans
Kidney Transplantation*
Male
Middle Aged
Safety
Time Factors
Grant Support
ID/Acronym/Agency:
AM13083/AM/NIADDK NIH HHS
Chemical
Reg. No./Substance:
59277-89-3/Acyclovir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High levels of complement fixing antibodies against cytomegalovirus in patients with primary Sjögre...
Next Document:  Renal tubular function in patients treated with high-dose cisplatin.